A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma
A phase 3 trial of Lenvatinib in hepatocellular carcinoma, run by CStone Pharmaceuticals, active and no longer recruiting.
Overview
A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma is a phase 3 interventional study registered as NCT04194775 by CStone Pharmaceuticals, with 534 participants enrolled, started 2019-12-13 and due to reach its primary completion in 2025-06-18. Interventions recorded: Nofazinlimab (CS1003)+Lenvatinib, Nofazinlimab (CS1003) Placebo+Lenvatinib. Conditions listed: Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialLEAP-002
Shares Lenvatinib, Hepatocellular carcinoma.
- TrialA Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepat
Shares Lenvatinib, Hepatocellular carcinoma.
- TrialDurvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma
Shares Lenvatinib, Hepatocellular carcinoma.
- TrialA Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
Shares Lenvatinib, Hepatocellular carcinoma.
- TrialLEAP-012
Shares Lenvatinib, Hepatocellular carcinoma.
- TrialStudy of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
Shares Lenvatinib, Hepatocellular carcinoma.
- TrialVisugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)
Shares Lenvatinib, Hepatocellular carcinoma.
- TrialPhase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
Shares Lenvatinib, Hepatocellular carcinoma.